May 7th 2024
Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
ctDNA Assays in CRC: Interpreting Clinical Findings
October 29th 2021Following presentation of a paper by Loupakis F, et al., Drs Liliana Bustamante and Richard Kim raise questions pertaining to the use of ctDNA as a biomarker when managing patients with metastatic colorectal cancer undergoing resection.
Presentation: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases
October 8th 2021Drs Liliana Bustamante and Richard Kim review “Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases,” by Loupakis F, et al.
MRD and Decision-Making in Early-Stage Colorectal Cancer
August 20th 2021This article reviews MRD and decision-making in early-stage colorectal cancer and includes insights from Christopher Lieu, MD, of the University of Colorado School of Medicine in Denver, and Daniel Ahn, DO, of the Mayo Clinic in Phoenix, AZ.
Examining Colon Cancer Outcomes in a Universal Health Care System Reveals High Survival Benefit
August 10th 2021United States Military Health System beneficiaries with colon cancer are more likely to have improved survival outcomes vs the general population, with a particularly notable benefit in Black patients.